Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Preclinical mouse solid tumour models: status quo, challenges and perspectivesNature reviews. Cancer, 2017-12, Vol.17 (12), p.751-765 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Dec 2017 ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/nrc.2017.92 ;PMID: 29077691Full text available |
|
2 |
Material Type: Article
|
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaborationPLoS medicine, 2012-05, Vol.9 (5), p.e1001216-e1001216 [Peer Reviewed Journal]COPYRIGHT 2012 Public Library of Science ;COPYRIGHT 2012 Public Library of Science ;2012 Altman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration. PLoS Med 9(5): e1001216. doi:10.1371/journal.pmed.1001216 ;Altman et al. 2012 ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1001216 ;PMID: 22675273Full text available |
|
3 |
Material Type: Article
|
Stakeholders welcome proposal on the European Health Data SpaceThe lancet oncology, 2022-12, Vol.23 (12), p.1492-1492 [Peer Reviewed Journal]2022 Elsevier Ltd ;2022. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(22)00691-X ;PMID: 36335972Full text available |
|
4 |
Material Type: Article
|
Improving human cancer therapy through the evaluation of pet dogsNature reviews. Cancer, 2020-12, Vol.20 (12), p.727-742 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-020-0297-3 ;PMID: 32934365Full text available |
|
5 |
Material Type: Article
|
Reengineering the clinical research enterprise to involve more community cliniciansImplementation science : IS, 2011-04, Vol.6 (1), p.36-36, Article 36 [Peer Reviewed Journal]COPYRIGHT 2011 BioMed Central Ltd. ;Copyright BioMed Central 2011 ;Copyright ©2011 Ryan et al; licensee BioMed Central Ltd. 2011 Ryan et al; licensee BioMed Central Ltd. ;ISSN: 1748-5908 ;EISSN: 1748-5908 ;DOI: 10.1186/1748-5908-6-36 ;PMID: 21463518Full text available |
|
6 |
Material Type: Article
|
The importance of patient-reported outcomes in clinical trials and strategies for future optimizationPatient related outcome measures, 2018-01, Vol.9, p.353-367 [Peer Reviewed Journal]COPYRIGHT 2018 Dove Medical Press Limited ;COPYRIGHT 2018 Dove Medical Press Limited ;2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Mercieca-Bebber et al. This work is published and licensed by Dove Medical Press Limited 2018 ;ISSN: 1179-271X ;EISSN: 1179-271X ;DOI: 10.2147/prom.s156279 ;PMID: 30464666Full text available |
|
7 |
Material Type: Article
|
Raise standards for preclinical cancer researchNature (London), 2012-03, Vol.483 (7391), p.531-533 [Peer Reviewed Journal]Copyright Nature Publishing Group Mar 29, 2012 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/483531a ;CODEN: NATUASFull text available |
|
8 |
Material Type: Article
|
Big data in basic and translational cancer researchNature reviews. Cancer, 2022-11, Vol.22 (11), p.625-639 [Peer Reviewed Journal]This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-022-00502-0 ;PMID: 36064595Full text available |
|
9 |
Material Type: Article
|
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialThe lancet oncology, 2021-08, Vol.22 (8), p.1162-1174 [Peer Reviewed Journal]2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00302-8Full text available |
|
10 |
Material Type: Article
|
Monica Bertagnolli: Director of the National Institutes of HealthThe Lancet (British edition), 2024-02, Vol.403 (10427), p.605-605 [Peer Reviewed Journal]2024 Elsevier Ltd ;2024. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(24)00262-9 ;PMID: 38368885Full text available |
|
11 |
Material Type: Article
|
A decade of immune-checkpoint inhibitors in cancer therapyNature communications, 2020-07, Vol.11 (1), p.3801-3801, Article 3801 [Peer Reviewed Journal]The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;The Author(s) 2020 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-17670-y ;PMID: 32732879Full text available |
|
12 |
Material Type: Article
|
Publication Trends in Acupuncture Research: A 20-Year Bibliometric Analysis Based on PubMedPloS one, 2016-12, Vol.11 (12), p.e0168123-e0168123 [Peer Reviewed Journal]COPYRIGHT 2016 Public Library of Science ;COPYRIGHT 2016 Public Library of Science ;2016 Ma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2016 Ma et al 2016 Ma et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0168123 ;PMID: 27973611Full text available |
|
13 |
Material Type: Article
|
What advanced cancer patients with limited treatment options know about clinical research: a qualitative studySupportive care in cancer, 2017-10, Vol.25 (10), p.3235-3242 [Peer Reviewed Journal]Springer-Verlag Berlin Heidelberg 2017 ;COPYRIGHT 2017 Springer ;Supportive Care in Cancer is a copyright of Springer, 2017. ;ISSN: 0941-4355 ;EISSN: 1433-7339 ;DOI: 10.1007/s00520-017-3734-4 ;PMID: 28488050Full text available |
|
14 |
Material Type: Article
|
Are innovation and new technologies in precision medicine paving a new era in patients centric care?Journal of translational medicine, 2019-04, Vol.17 (1), p.114-114, Article 114 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 1479-5876 ;EISSN: 1479-5876 ;DOI: 10.1186/s12967-019-1864-9 ;PMID: 30953518Full text available |
|
15 |
Material Type: Article
|
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitorsNature reviews. Drug discovery, 2018-11, Vol.17 (12), p.854-855 [Peer Reviewed Journal]Copyright Nature Publishing Group Dec 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2018.210Full text available |
|
16 |
Material Type: Article
|
WHO, WHAT AND WHERE IS THE CLINICAL TRANSLATIONAL RESEARCH CENTEROncology nursing forum, 2022-03, Vol.49 (2), p.E134-E135 [Peer Reviewed Journal]Copyright Oncology Nursing Society Mar 2022 ;ISSN: 0190-535X ;EISSN: 1538-0688Full text available |
|
17 |
Material Type: Article
|
Deborah JamesThe Lancet (British edition), 2022-08, Vol.400 (10350), p.426-426 [Peer Reviewed Journal]2022 Elsevier Ltd ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)01428-3Full text available |
|
18 |
Material Type: Article
|
Obstacles, Opportunities and Priorities for Advancing Metastatic Breast Cancer ResearchCancer research, 2017-07, Vol.77 (13), p.3386-3390 [Peer Reviewed Journal]2017 American Association for Cancer Research. ;Copyright American Association for Cancer Research, Inc. Jul 1, 2017 ;ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/0008-5472.CAN-17-0232 ;PMID: 28601794Full text available |
|
19 |
Material Type: Article
|
Lysosomal lipid peroxidation mediates immunogenic cell deathThe Journal of clinical investigation, 2023-04, Vol.133 (8), p.1-3 [Peer Reviewed Journal]Copyright American Society for Clinical Investigation Apr 2023 ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/JG164596Full text available |
|
20 |
Material Type: Article
|
Data Sharing from Clinical Trials — A Research Funder’s PerspectiveThe New England journal of medicine, 2017-11, Vol.377 (20), p.1990-1992 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsb1708278 ;PMID: 29141170Full text available |